Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
复制标题
DOI：
10.1158/1078-0432.ccr-12-0151
复制
发表时间：
2012-04-01
期刊：
影响因子：
--
通讯作者：
Llovet JM
中科院分区：
文献类型：
--
作者：
Villanueva A;Llovet JM
索拉非尼治疗后进展的晚期肝细胞癌患者需要二线治疗。本文报道的2期研究中的布立尼布阳性信号尚未在3期试验中得到证实。确定索拉非尼耐药的分子机制应该指导这种情况下的药物开发策略。
There is a need for second line therapies in patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals of brivanib in phase 2 studies reported herein have yet to be confirmed in phase 3 trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting.